CytoSorbents Corporation filed an 8-K announcing a $6.25 million common stock financing and a concurrent amendment to its Avenue Capital credit facility, both disclosed on November 20, 2026.

Key Highlights

  • Registered direct offering: The company priced 556,681 shares at $4.94 per share and 96,527 shares to directors and certain executive officers at $5.18 per share, plus pre-funded warrants for up to 151,822 shares at $4.939 each.
  • Gross cash proceeds: The offering is expected to generate approximately $4.0 million, with approximately 75% subscribed by existing shareholders and members of management and the Board of Directors.
  • Debt reduction: Total outstanding principal is reduced by $5.25 million, from $17.5 million to $12.25 million, through $3.0 million in cash repayment and $2.25 million satisfied via 455,465 shares issued to Avenue Venture Opportunities Fund, L.P. at $4.94 per share.
  • Interest savings: The company expects to save approximately $0.7 million in interest expense over 12 months following the debt reduction.
  • Maturity extended: The Avenue loan maturity date is extended from July 1, 2027 to July 1, 2028, with interest-only payments extended through March 31, 2028.
  • New conversion rights: Avenue's existing $2.0 million conversion right is replaced with rights to convert up to $3.0 million at $6.916 per share and up to an additional $3.125 million at $8.645 per share, subject to timing conditions.

CytoSorbents Restructures Avenue Credit Facility Alongside At-Market Equity Offering

CytoSorbents Corporation (NASDAQ:CTSO) disclosed a $6.25 million financing consisting of a registered direct offering and a concurrent amendment to its existing loan agreement with Avenue Capital Group. According to the filing, the offering was priced at-the-market under Nasdaq rules and is expected to close on or about November 20, 2026, subject to customary closing conditions. H.C. Wainwright and Co. is acting as exclusive placement agent, and WBB Securities, LLC is acting as financial advisor.

The company disclosed it intends to use net proceeds primarily to repay $3.0 million in outstanding principal under the Avenue loan, along with a $52,500 prepayment fee and a $270,000 final payment, with the remainder for general corporate and working capital purposes. Concurrently, $2.25 million in Avenue principal is being satisfied through the issuance of 455,465 shares of common stock to Avenue Venture Opportunities Fund, L.P. at $4.94 per share. The filing noted that these shares are issued in addition to those sold in the offering and will not generate additional cash proceeds to the company.

The Third Amendment to Loan Documents, dated November 19, 2026, also modifies certain beneficial ownership limitations and financial covenants, provides certain registration rights, and adds a back-end fee of $250,000 payable on July 1, 2028, which the filing states is waived if Avenue achieves a net profit of at least 300% on the initial $2.25 million repayment shares. A further three-month extension of the interest-only period is available if the company has received FDA marketing approval for DrugSorb-ATR by March 31, 2028, subject to other conditions, according to the filing.

What Was Disclosed

CytoSorbents announced a $6.25 million at-market equity financing and a concurrent amendment to its Avenue Capital loan, reducing total debt by $5.25 million to $12.25 million, extending loan maturity to July 1, 2028, and replacing Avenue's prior conversion rights with new, higher-priced conversion terms.